B-cell translocation gene 1 protein (BTG1)

B-cell translocation gene 1 protein (BTG1) is a member of the anti-proliferative BTG/TOB protein family and is characterized by two conserved domains (Box A and Box B). It functions mainly as a transcriptional coactivator and tumor suppressor, suppressing cell proliferation, promoting G0/G1 cell cycle arrest, inducing apoptosis, and fostering cell differentiation. BTG1 is expressed predominantly in the nucleus and cytoplasm, especially in quiescent cells of tissues such as the pancreas, heart, and hematopoietic system. It exerts molecular effects by interacting with various nuclear receptors, transcription factors (including HOXB9), and components of the CCR4-NOT mRNA deadenylation complex (notably CNOT7 and CNOT8), thereby influencing both gene-specific and global mRNA turnover. Clinically, BTG1 alterations—particularly loss of function and recurrent mutations—are implicated in B-cell malignancies (notably diffuse large B-cell lymphoma and B-cell precursor acute lymphoblastic leukemia) and are associated with poor treatment outcomes and aggressive disease. Its expression modulates cellular response to chemotherapeutic agents and is being studied as a prognostic biomarker in oncology.

Other names

Protein BTG1APRO2BTG anti-proliferation factor 1B-cell translocation gene 1Anti-proliferative protein BTG1

Enhancement of chemosensitivity via induction of apoptosis; Cell cycle arrest induction (not drug-specific but a pathway targeted by overexpression or modulation of BTG1)